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Abstract 
Background: Regarding high prevalence of common cold and sinusitis in Chaharmahal and Bakhtiari Province 
and the lack of studies on patients referring hospitals in this province, this study was conducted to determine and 
compare the efficacy and side effects of azithromycin and co-amoxiclav. 
Methods: This study was a double-blinded randomized clinical trial. The study population of this clinical trial 
was consisted of 90 patients with acute sinusitis aged 12-65 years. At least two major criteria or one major 
criterion and two minor criteria with duration of at least 7 days and at most 28 days, were some of the sinusitis 
diagnostic criteria for inclusion of the patients into the study. The patients were examined for symptoms prior to 
and twice after the treatment. The treatment was administration with 500 mg azithromycin tablet per day for 
three days in group 1 (G1) and 625 mg co-amoxiclav tablet every 8 h for 10 days in group 2 (G2). The data were 
analyzed by repeated measures analysis of variance, independent t-test, and chi-square in Stata software and P < 
0.05 was considered significant. 
Results: Mean±Standard deviation age of all patients was 32.14±9.91 years. Out of 90 participants in the study, 
50 (55.56%) were male and the rest were female. The patients’ symptoms were quantitatively similar in the two 
groups (22.3±2 and 22.2±1.9 in G1 and G2, respectively) prior to the intervention. The score at second 
examination decreased to 3.7±2.1 in G1 and to 9.4±2.7 in G2, significantly different from that prior to 
intervention and between the two groups (P<0.001). Although the score decreased in the two groups at third 
examination, it was not significant in the two groups (P=0.652). The cure rate in azithromycin group was derived 
87.5% and 88%, and in co-amoxiclav group 32.4% and 83.3% at the days 5 and 10 of treatment, respectively. 
The most prevalent side effects in the two groups were diarrhea and nausea. The prevalence of diarrhea was 
obtained 21% and 33% in G1 and G2, respectively.   
Conclusion: No significant difference in side effects was seen between the two groups. Although the cure was 
faster in the patients treated with azithromycin than those treated with co-amoxiclav, co-amoxiclav is still 
considered as adequately working against acute sinusitis bacterial pathogens. In view of this efficacy, 
co-amoxiclav seems to lead to no drug resistance and could be used to treat the patients. 
Keywords: Azithromycin, co-amoxiclav, acute sinusitis 
1. Introduction 
There are more than a billion cases of viral and bacterial rhinosinusitis annually in the United States (Flint et al., 
2014). It is estimated that it costs 5.8 billion $ per year (Demury GP, Wald ER). Sinusitis has got many 
complications like mucous retention cyst, mucocele, inflammatory polyps and orbital complications. Orbital 
complications of paranasal sinus infection include: preseptal orbital edema, superior ophthalmic vein thrombosis, 
cavernous sinus thrombosis and blindness. 
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Different treatments of sinusitis have been compared and reported since 1982, with little difference among them 
(von Sydow, Axelsson, & Jensen, 1982). The clinical cure rate was reported 73.9% for azithromycin and 73.3% 
for co-amoxiclav in a study (Casiano, 1991). Cefpodoxime proxetil was demonstrated as clinically working as 
amoxicillin for treating acute bacterial maxillary sinusitis (von Sydow, Savolainen, & Soderqvist, 1995). In view 
of the above studies and in a meta-analysis by Ioannidis et al., azithromycin was reported to lead to the clinical 
failure rates similar to the other antibiotics (Ioannidis, Contopoulos-Ioannidis, Chew, & Lau, 2001). Clement 
reported that the total rate of clinical response was 87.5% for azithromycin and 83.7% for co-amoxiclav 
(Clement & de Gandt, 1998). The findings have indicated that antimicrobial therapy in short course (≤5 days, ≤3 
days) for azithromycin could be as effective as and, occasionally, more effective than conventional therapies in 
long courses (10- to 14-day) (Guay, 2003). 
Given cold climate, high altitude,high prevalence of sinusitis in Chaharmahal and Bakhtiari Province, lack of 
studies on patients referring hospitals in this topic in this province (Amani, Kheiri, & Ahmadi, 2015), and the 
availability of azithromycin and co-amoxiclav as two drugs of choice, this study was conducted to determine and 
compare the efficacy and side effects of azithromycin and co-amoxiclav. 
2. Materials and Methods  
This study was a randomized clinical trial where both the allocator and examiner of the therapies were blinded. 
The study protocol was registered as IRCT201505106252N7 in Iranian Registry of Clinical Trials. The research 
adhered to Declaration of Helsinki, was approved by the Ethics Committee of the university (number : 92-6-24), 
and informed consent was obtained from all the participants. 
Study population consisted of the patients with acute sinusitis aged 12-65 years. At least two major criteria or 
one major criterion and two minor criteria with duration of at least 7 days and at most 28 days have entered into 
the study. Pain or pressure in the face, facial fullness or congestion, nasal obstruction, nasal or postnasal purulent 
discharge, hyposmia or anosmia, and fever were considered as major criteria, and headache, halitosis, fatigue, 
toothache, ear pain or fullness, and cough as minor criteria. Chronic sinusitis, recurrent sinusitis, anatomic 
abnormalities, pregnancy or lactation, chronic diseases(renal failure,chronic liver and lung diseasis,diabetis 
mellitus and…) hypersensitivity to co-amoxiclav or azithromycin, congenital or acquired immunodeficiency, 
taking antibiotics one month before treatment, and the ages under 12 and over 65 years were considered as 
exclusion criteria.  
90 patients referring the clinic were randomly entered the study. Patients were assigned to either of the groups of 
study by convenience randomization with equal probability. The patients were randomly divided into two groups 
that one group was treated with azithromycin and the other group was received co amoxiclav. The patients were 
examined for the symptoms and side effects such as diarrhea, nausea, and abdominal bloating at baseline and at 
the 5th and 10th day of treatment. 
Pain or pressure in the face, facial fullness or congestion, nasal obstruction, nasal or postnasal purulent discharge, 
hyposmia or anosmia, fever, headache, halitosis, fatigue, toothache, ear pain or fullness, cough, and nasal 
hyperemia were assigned as the items of examination. All examinations were done by an otorhinolaryngologist. 
In addition to qualitative examination of the patients, the outcome of examinations was quantitatively recorded 
as 0-26 for the above items in examination form. The patients who suffered more severe sinusitis and presented 
with more clinical symptoms were assigned higher scores. The patients who failed to adhere to therapeutic 
regimen or were not accessible throughout whole follow-up period were excluded from the study.  The 
intervention consisted of 0.5% phenylephrine drop 3 drops 3 times a day for 2 days, nasal irrigation with normal 
saline 3 times a day, and one 500 mg azithromycin tablet a day for 3 days in group 1, and 0.5% phenylephrine 
drop 3 drops 3 times a day for 2 days, nasal irrigation with normal saline 3 times a day, and one 625 mg 
co-amoxiclav tablet every 8 hours for 10 days in group 2. The data were analyzed by repeated measures analysis 
of variance (ANOVA), independent t-test, and chi square in STATA software. The level of significance was 
considered < 0.05. The presuppositions of repeated measures ANOVA were investigated, and normal distribution 
and equality of variances (homoscedasticity) were established. Sphericity presupposition was not established and 
therefore Greenhouse-Geisser was used.
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3. Results  
Of the 90 participants, 50 (55.56%) were male and the rest were female. Of the 50 men, 25 underwent treatment 
with azithromycin and the rest with co-amoxiclav. Furthermore, of 40 women, 20 underwent treatment with 
azithromycin and the rest with co-amoxiclav. Mean ± standard deviation age of all the studied patients was 32.14 
± 9.91 years. Table 1 shows mean age of the patients for gender and treatment groups. The most prevalent 
complaint in the patients was nasal obstruction (97.4%) followed by pain or pressure in face (94.8%) and nasal 
or postnasal purulent discharge (94.8%).  
 
Table 1. Mean and standard deviation age of the patients 
P value female male Treatment group 
0.683 31.55 ± 7.73 31.56 ± 7.7  Azithromycin 
0.327 29.2 ± 7.23 32.72 ± 8.8 Co-amoxiclav 
0.353 30.37 ± 7.48 32.14 ± 9.91 Total 
 
The frequency and percentage of the examined symptoms prior to and at two turns of examinations after 
treatment in all the patients and for either of treatment groups are shown in Table 2.  
 
Table 2. Symptoms of disease prior to and after treatment for groups of study 
Prior to intervention Day 5 of intervention Day 10 of intervention Symptom 
 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 
Frequency% Frequency % Frequency% Frequency% Frequency% Frequency % 
40 95.2 34 94.45 11.927 75 5 11.9 6 16.7 Pain or pressure in 
face 
38 95.2 32 88.94 9.523 63.94 9.5 5 13.9 Facial fullness or 
congestion 
41 97.6 35 97.25 11.924 66.75 11.9 6 7/16  Nasal obstruction 
40 95.2 34 94.45 11.923 63.95 11.9 6 16.7 Nasal purulent 
discharge 
29 69 26 72.24 9.515 41.74 9.5 4 11.1 Hyposmia 
10 23.8 7 19.44 9.55 13.94 9.5 1 2.8 Fever 
36 85.7 32 88.96 14.320 55.65 11.9 4 11.1 Headache 
22 52.4 21 58.34 9.517 47.24 9.5 3 8.3 Halsitosis 
15 35.7 12 33.31 2.46 16.71 2.4 2 5.6 Fatigue 
4 9.5 3 8.31 2.42 5.61 2.4 0 0 Toothache 
11 26.2 9 25 0 0 7 19.40 0 2 5.6 Cough 
10 23.8 6 16.72 4.85 13.92 4.8 1 2.8 Ear pain or 
fullness 
42 100 37 1005 11.933 91.75 11.9 6 16.7 Rhinoscopy 
examination 
 
The patients’ symptoms were quantitatively similar in the two groups (22.3±2 and 22.2±1.9 in group 1 and group 
2, respectively) prior to the intervention. The score at second examination decreased to 3.7±2.1 in group 1 and to 
9.4±2.7 in group 2, significantly different from that prior to intervention and between the two groups (P<0.001). 
Although the score decreased in the two groups at third examination, it was not significant in the two groups 
(P=0.652). The cure rate in azithromycin group was derived 87.5% and 88%, and in co-amoxiclav group 32.4% 
and 83.3% at the days 5 and 10 of treatment, respectively. Cure was defined the patients without any signs and 
www.ccsenet.org/gjhs Global Journal of Health Science Vol. 8, No. 11; 2016 
181 
 
symptoms of sinusitis. The most prevalent side effects in the two groups were diarrhea and nausea. The 
prevalence of diarrhea was obtained 21% and 33% in group 1 and group 2, respectively.   
4. Discussion 
In this study, the efficacy of two pharmacological regimens on treatment of acute sinusitis was assessed .Because 
culture of the sinus secretion is aggressive and has risk of iatrogenic infection and also being expensive and 
requires a minimum 72 hours for implementation,thus diagnosis and treatment of bacterial sinusitis are often 
fulfilled clinically and empirical. In different studies, the patients’ purulent discharge, nasal obstruction and 
fullness, and pressure and pain in face have been considered as main criteria for diagnosing acute sinusitis 
(Lemiengre, van Driel, Merenstein, Young, & De Sutter, 2012; Riechelmann, Giotakis, & Kral, 2013;   
Nematian-Samani, & Mosges, 2014; Smith, Ference, Evans, Tan, Kern, & Chandra, 2015). In a study the 
efficacy and side effects of 500 mg azithromycin taken daily for 3 and 6 days were compared with those of 
co-amoxiclav 500/125 mg taken 3 times a day for 10 days with regard to treatment of acute sinusitis in adults . 
The efficacy of azithromycin was obtained 88.8% and 89.3% for 3 and 6 days, respectively, and that of 
co-amoxiclav was reported 84.9% (Henry, Riffer, Sokol, Chaudry, & Swanson, 2003). In our study, the cure rate 
in azithromycin group was 88% and in co amoxiclav group was 83/3% at tenth day, this shows our findings are 
in line with this study. 
In another study 4.9% of patients in the azithromycin group and 8.1% in the amoxicillin group reported side 
effects. Most side effects were gastrointestinal and were reported by 4 of 5 (3 amoxicillin, 1 azithromycin) 
patients. All side effects were mild, and only minor abnormalities in laboratory findings were reported in both 
groups. No patient declined to participate in the study because of side effects. In this study, a 5-day course (one 
dose a day) of azithromycin was demonstrated to have efficacy, safety, and tolerability, similar to those of a 
10-day course (3 doses a day) of amoxicillin for the treatment of acute bacterial sinusitis (Casiano, 1991), 
similarly in our study the side effects were gastrointestinal but the prevalence of side effects were more than 
Casiano’s study. 
In a per protocol analysis, 117 patients in the cefpodoxime group and 113 in the amoxicillin group were 
compared for clinical efficacy. The clinical response rates were derived 96% and 91%, respectively, and the 
corresponding figures in the intent-to-treat analysis were 130 and 128 patients, with clinical response rates of 
93% and 88%, respectively. Cefpodoxime proxetil was clinically found as effective as amoxicillin for the 
treatment of acute bacterial maxillary sinusitis. It was more effective on resolving Haemophilus influenzae and 
more efficient in enhancing the radiological score. Side effects were reported in 20% of cefpodoxime-treated 
patients and 16% of amoxicillin-treated patients with no statistically significant difference between the groups 
(von Sydow, Savolainen, & Soderqvist, 1995). 
Microbiological responses to both drugs were acceptable, and only 5 patients in each group had a persistent 
infection after treatment. Both drugs were well tolerated and caused similar adverse events, which were mostly 
gastrointestinal. Azithromycin and co-amoxiclav were similar for efficacy and tolerability, while azithromycin’s 
shorter simpler and dosing regimen may be preferable with regard to compliance and cost (Clement & de Gandt, 
1998). 
A meta-analysis of randomized controlled trials compared 3-5 days of azithromycin with other antibiotics 
conventionally taken in longer courses for the treating upper respiratory tract infections. The study consisted of 
19 comparisons (3421 patients) for acute otitis media, 11 comparisons (including 1742 patients) for acute 
sinusitis, and 16 comparisons (including 2447 patients) for acute pharyngitis; azithromycin had comparable 
clinical failure rates to the other antibiotics. There were no significant differences in bacteriological outcomes, as 
well. Azithromycin was withdrawn because of adverse effects by only 37 of 4870 (0.8%) patients. Short courses 
of azithromycin are as effective as longer courses of other antibiotics for upper respiratory tract infections. 
Despite easy dosing, this regimen for the treatment of these common infections has been increasing in cost, 
where often no other antibiotic may be prescribed (Ioannidis, Contopoulos-Ioannidis, Chew, & Lau, 2001). 
In a study, a significantly quicker healing of signs and symptoms of sinusitis has been noted in the 
azithromycin-treated patients. By the end of treatment (days 10-12), 95% and 74% of the patients in the 
azithromycin and amoxicillin/clavulanate groups were treated (Klapan, Culig, Oreskovic, & Matrapazovski, 
Radosevic, 1999). There is a difference in result between our study and this study, it can be related to the number 
of patients, on the other hand we used different pharmacological products that it can be the another reason of this 
contrast. 
The treatment results of 27 various treatment methods were compared in 1320 cases of acute maxillary sinusitis 
(2039 maxillary sinuses). The treatment regimens were not found to be much different in therapeutic effect, 
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irrespective of treatment with antral drainage alone, antibiotics alone or their combination (von Sydow, Axelsson, 
& Jensen, 1982). 
5. Conclusion 
The cure rate in azithromycin group was derived 87.5% and 88%, and in co-amoxiclav group 32.4% and 83.3% 
at the day 5 and 10 of treatment, respectively. Diarrhea and nausea were the most prevalent side effects in the 
two groups. The prevalence of diarrhea was 21% in group 1 and 33% in group 2 respectively and no significant 
difference in side effects was seen between the two groups of study. Although the patients treated with 
azithromycin were cured more quickly than those treated with co-amoxiclav, co-amoxiclav is still known as 
being satisfactorily effective on bacterial pathogens of acute sinusitis. Because of this efficacy, co-amoxiclav 
seems to cause no drug resistance and could be used to cure the disease. 
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